Status:
UNKNOWN
Autologous CIK Cells Infusion for the Treatment of Lung Cancer: a Randomized Controlled Study
Lead Sponsor:
Third Military Medical University
Conditions:
Lung Cancer
Eligibility:
All Genders
18-70 years
Brief Summary
To study the efficacy and safety of autologous CIK cells infusion for the treatment of lung cancer.
Detailed Description
A randomized controlled trail on the efficacy and safety of autologous cytokine-induced killer (CIK) cells infusion treatment in advanced primary lung cancer
Eligibility Criteria
Inclusion
- 18\~70 year old, KPS score \>50 points, estimate survival \> 3 months;
- Primary lung cancer patients after chemotherapy or radiation therapy;
- Primary lung cancer patients after targeted therapy;
- Primary lung cancer patients with lung function can not accept operation or unwilling to operation;
- Primary lung cancer recurrence or surgery can't complete resection;
- Primary lung cancer patients after intervention therapy(I125 implanted, freezing, rf, etc.);
- No serious mental illness and no serious heart, liver, kidney diseases, unincorporated other potentially lethal diseases;
- Patients Voluntary attempt, and informed consent.
Exclusion
- History of cardiovascular disease: congestive heart failure \> New York heart association (NYHA) level II, unstable angina patients (resting when the angina symptoms) or new happen angina pectoris (recent 3 months) or recent 6 months of myocardial infarction;
- Cachexia; or other deadly diseases;
- Liver function laboratory ALT, AST more than normal limits on 2.0 times ; Or kidney TBIL, BUN more than normal limits on 1.0 times , or Cr more than normal upper limit;
- Active infection;
- Pregnant or lactating women
- At present Is receiving other cancer treatment (such as chemotherapy, radiation therapy, chemotherapy, immunosuppressants and thrombosis, targeted agents);
- Now or recently will join another experimental clinical study ;
- Other situations that the researchers considered unsuitable for this study (such as mental illness, drug abuse, HIV infections, etc.), or influence on the results of clinical trials for analysis.
Key Trial Info
Start Date :
December 1 2011
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 1 2013
Estimated Enrollment :
120 Patients enrolled
Trial Details
Trial ID
NCT01498055
Start Date
December 1 2011
End Date
December 1 2013
Last Update
March 22 2012
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Liang Gong
Chongqing, Chong Qing, China, 400038